文献速递乳腺癌

辅助紫杉醇联合曲妥珠单抗治疗淋巴结阴性HER2阳性乳腺癌:开放标签单臂2期APT试验的10年最终分析

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
PubMed 文献 · Lancet Oncol · 2023-01-01

该开放标签单臂2期研究纳入406例小肿瘤(≤3cm)、淋巴结阴性、HER2阳性乳腺癌患者,接受每周紫杉醇联合曲妥珠单抗辅助治疗。中位随访10.8年,10年无浸润性疾病生存率为91.3%,总生存率为94.3%。作者认为该方案是合理的治疗标准,HER2DX基因组工具可能有助于细化预后。

要点

  • 10年无浸润性疾病生存率为91.3%(95%CI 88.3-94.4),总生存率为94.3%(95%CI 91.8-96.8)。
  • HER2DX风险评分每增加10单位与无浸润性疾病生存显著相关(HR 1.24,95%CI 1.00-1.52;p=0.047)。
  • 作者认为辅助紫杉醇联合曲妥珠单抗是小肿瘤、淋巴结阴性、HER2阳性乳腺癌的合理治疗标准。

核心结论

  • 辅助紫杉醇联合曲妥珠单抗是小肿瘤、淋巴结阴性、HER2阳性乳腺癌患者的合理治疗标准。
  • HER2DX基因组工具可能有助于细化该人群的预后判断。

研究设计与样本

  • 开放标签、单臂、2期研究,从美国13个城市的16家机构招募患者。
  • 纳入年龄≥18岁、肿瘤≤3cm、淋巴结阴性、HER2阳性、ECOG体能状态0-1分的乳腺癌患者。
  • 2007年10月29日至2010年9月3日共入组410例,406例接受方案定义治疗并纳入分析。
  • 治疗方案为每周静脉紫杉醇80mg/m²联合静脉曲妥珠单抗(负荷剂量4mg/kg,后续2mg/kg)共12周,随后曲妥珠单抗(每周2mg/kg或每3周6mg/kg)40周,完成全年曲妥珠单抗治疗。
  • 主要终点为3年无浸润性疾病生存,本次报告10年生存结局,并探索性分析HER2DX基因组工具。

主要发现

  • 入组时平均年龄55岁(SD 10.5),405例(99.8%)为女性,1例(0.2%)为男性。
  • 350例(86.2%)为白人,28例(6.9%)为黑人或非裔美国人,272例(67.0%)为激素受体阳性疾病。
  • 中位随访10.8年(IQR 7.1-11.4),406例中观察到31例无浸润性疾病生存事件,其中同侧局部区域复发6例(19.4%)、新发对侧乳腺癌9例(29.0%)、远处复发6例(19.4%)、全因死亡10例(32.3%)。
  • 10年无浸润性疾病生存率为91.3%(95%CI 88.3-94.4),10年无复发生存间期为96.3%(95%CI 94.3-98.3)。
  • 10年总生存率为94.3%(95%CI 91.8-96.8),10年乳腺癌特异性生存率为98.8%(95%CI 97.6-100)。

临床怎么用

  • 作者认为辅助紫杉醇联合曲妥珠单抗是小肿瘤、淋巴结阴性、HER2阳性乳腺癌的合理治疗标准。
  • 作者认为HER2DX基因组工具可能有助于细化该人群的预后判断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to report on long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and to establish potential biomarkers to predict prognosis. METHODS: In this open-label, single-arm, phase 2 study, patients aged 18 years or older, with small (≤3 cm), node-negative, HER2-positive breast cancer, and an Eastern Cooperative Oncology Group performance status of 0-1, were recruited from 16 institutions in 13 cities in the USA. Eligible patients were given intravenous paclitaxel (80 mg/m2) with intravenous trastuzumab (loading dose of 4 mg/kg, subsequent doses 2 mg/kg) weekly for 12 weeks, followed by trastuzumab (weekly at 2 mg/kg or once every 3 weeks at 6 mg/kg) for 40 weeks to complete a full year of trastuzumab. The primary endpoint was 3-year invasive disease-free survival. Here, we report 10-year survival outcomes, assessed in all participants who received protocol-defined treatment, with exploratory analyses using the HER2DX genomic tool. This study is registered on ClinicalTrials.gov, NCT00542451, and is closed to accrual. FINDINGS: Between Oct 29, 2007, and Sept 3, 2010, 410 patients were enrolled and 406 were given adjuvant paclitaxel and trastuzumab and included in the analysis. Mean age at enrolment was 55 years (SD 10·5), 405 (99·8%) of 406 patients were female and one (0·2%) was male, 350 (86·2%) were White, 28 (6·9%) were Black or African American, and 272 (67·0%) had hormone receptor-positive disease. After a median follow-up of 10·8 years (IQR 7·1-11·4), among 406 patients included in the analysis population, we observed 31 invasive disease-free survival events, of which six (19·4%) were locoregional ipsilateral recurrences, nine (29·0%) were new contralateral breast cancers, six (19·4%) were distant recurrences, and ten (32·3%) were all-cause deaths. 10-year invasive disease-free survival was 91·3% (95% CI 88·3-94·4), 10-year recurrence-free interval was 96·3% (95% CI 94·3-98·3), 10-year overall survival was 94·3% (95% CI 91·8-96·8), and 10-year breast cancer-specific survival was 98·8% (95% CI 97·6-100). HER2DX risk score as a continuous variable was significantly associated with invasive disease-free survival (hazard ratio [HR] per 10-unit increment 1·24 [95% CI 1·00-1·52]; p=0·047) and recurrence-free interval (1·45 [1·09-1·93]; p=0·011). INTERPRETATION: Adjuvant paclitaxel and trastuzumab is a reasonable treatment standard for patients with small, node-negative, HER2-positive breast cancer. The HER2DX genomic tool might help to refine the prognosis for this population. FUNDING: Genentech.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tolaney SM, Tarantino P, Graham N, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023. PMID: 36858723. doi:10.1016/S1470-2045(23)00051-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。